Glaucoma is an eye disease caused by raised pressure within the eye.
It is the number one cause of irreversible blindness worldwide, affecting nearly 80 million people.
Glaucoma is especially common, more severe, and
more difficult to treat within the African population.
The OptiShunt device is Liqid Medical's flagship device. OptiShunt is a patented ocular implant designed to be the world's first definitive treatment for severe and refractory glaucoma and pioneer a new class of glaucoma surgery known as Maximally Effective Glaucoma Surgery (MEGS).
First-in-Man clinical trials are planned to commence at Groote Schuur Hospital, Cape Town, in the last quarter of 2019.
Ask the experts
“Brilliant concept! Seems to make so much sense... Exciting idea.”
"We're proud to be involved in this innovative project."
- Raphael Smith, Managing director BMEC Engineering
"A great concept and represents a paradigm shift in our traditional thinking about glaucoma management... exciting work"
- Prof Colin Cook, head of Ophthalmology, Groote Schuur and Redcross hospital
"Real hope for definitive prevention of blindness caused by glaucoma."
The iFlow is an ocular device designed to make glaucoma surgery faster, safer, and cheaper. PCT patents have been filed and early prototyping and cadaver studies have been completed. Design Innovation Seed funding has been approved by the Craft and Design Institute and clinical trials and CE marking are planned for 2019.
The OrbiTract is an ophthalmic instrument designed to improve tissue visualisation during orbital and ocular surgery. Device prototyping and cadaver studies have been completed. Biocompatibility studies are underway and clinical trials are planned for the first quarter of 2019.